Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicia Gray

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
AIDS and Behavior|October 10, 2003
A qualitative investigation of antiretroviral therapy among injection drug usersAlfred Pach, Felicia Gray Cerbone, Dean R Gerstein
Addiction (Abingdon, England)|July 30, 2002
HIV risk behaviors in African-American drug injector networks: implications of injection-partner mixing and partnership characteristicsRobert A Johnson, Dean R Gerstein, Alfred Pach, et al.
Plos Computational Biology|November 9, 2013
An evolution-based approach to De Novo protein design and case study on Mycobacterium tuberculosisPralay Mitra, David Shultis, Jeffrey R Brender, et al.
Journal of Medicinal Chemistry|January 2, 2025
Development of PRC1 Inhibitors Employing Fragment-Based Approach and NMR-Guided OptimizationYiwu Yao, Miranda L Simes, Weijiang Ying, et al.
Nature Communications|November 10, 2016
BMI1 regulates PRC1 architecture and activity through homo- and hetero-oligomerizationFelicia Gray, Hyo Je Cho, Shirish Shukla, et al.
Nature Communications|August 26, 2025
Harnessing free energy calculations for kinome-wide selectivity in drug discovery campaigns with a Wee1 case studyJennifer Lynn Knight, Anthony J Clark, Jiashi Wang, et al.
ACS Medicinal Chemistry Letters|March 19, 2025
Exploiting Solvent Exposed Salt-Bridge Interactions for the Discovery of Potent Inhibitors of SOS1 Using Free-Energy Perturbation SimulationsAbba E Leffler, Evelyne M Houang, Felicia Gray, et al.
Journal of Medicinal Chemistry|December 13, 2024
<i>In Silico</i> Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal InjuryH Rachel Lagiakos, Yefen Zou, Hideyuki Igawa, et al.
Journal of Molecular Biology|January 10, 2019
Changing the Apoptosis Pathway through Evolutionary Protein DesignDavid Shultis, Pralay Mitra, Xiaoqiang Huang, et al.
Nature Chemical Biology|June 22, 2021
Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domainShirish Shukla, Weijiang Ying, Felicia Gray, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
AIDS and Behavior|October 10, 2003
A qualitative investigation of antiretroviral therapy among injection drug usersAlfred Pach, Felicia Gray Cerbone, Dean R Gerstein
Addiction (Abingdon, England)|July 30, 2002
HIV risk behaviors in African-American drug injector networks: implications of injection-partner mixing and partnership characteristicsRobert A Johnson, Dean R Gerstein, Alfred Pach, et al.
Plos Computational Biology|November 9, 2013
An evolution-based approach to De Novo protein design and case study on Mycobacterium tuberculosisPralay Mitra, David Shultis, Jeffrey R Brender, et al.
Journal of Medicinal Chemistry|January 2, 2025
Development of PRC1 Inhibitors Employing Fragment-Based Approach and NMR-Guided OptimizationYiwu Yao, Miranda L Simes, Weijiang Ying, et al.
Nature Communications|November 10, 2016
BMI1 regulates PRC1 architecture and activity through homo- and hetero-oligomerizationFelicia Gray, Hyo Je Cho, Shirish Shukla, et al.
Nature Communications|August 26, 2025
Harnessing free energy calculations for kinome-wide selectivity in drug discovery campaigns with a Wee1 case studyJennifer Lynn Knight, Anthony J Clark, Jiashi Wang, et al.
ACS Medicinal Chemistry Letters|March 19, 2025
Exploiting Solvent Exposed Salt-Bridge Interactions for the Discovery of Potent Inhibitors of SOS1 Using Free-Energy Perturbation SimulationsAbba E Leffler, Evelyne M Houang, Felicia Gray, et al.
Journal of Medicinal Chemistry|December 13, 2024
<i>In Silico</i> Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal InjuryH Rachel Lagiakos, Yefen Zou, Hideyuki Igawa, et al.
Journal of Molecular Biology|January 10, 2019
Changing the Apoptosis Pathway through Evolutionary Protein DesignDavid Shultis, Pralay Mitra, Xiaoqiang Huang, et al.
Nature Chemical Biology|June 22, 2021
Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domainShirish Shukla, Weijiang Ying, Felicia Gray, et al.
Pageof 1